DL
Dasom Lee
Also known as: Caroline
Eastern Virginia Medical School, University of California, Berkeley
Research areas: Medicine · Oncology · CAR-T cell therapy research · Lymphoma Diagnosis and Treatment · T-cell and B-cell Immunology
0000-0002-7468-7576
Employment
Employment history is unavailable.
Education
- 2014 - 2018
- 2007 - 2011
Projects & Funding
-
Optimizing cellular and humoral immunity to pneumococcus by vaccination with pneumococcal 13-valent conjugate vaccine before and after CD19-targeted CAR T-cell therapy University of South Florida2019 - 2020
Publications (32)
- Lisocabtagene Maraleucel for Richter's Transformation—A Case Series Save
- Dynamics of Circulating Tumor DNA As a Predictor of Outcomes with Lisocabtagene Maraleucel in Relapsed or Refractory Large B-Cell Lymphoma from the Transcend NHL-001 Study Save
- Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) Save
- Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy in Octogenarian Patients (Aged ≥ 80) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) Save
- Single Institution Analysis of Lymphoma Treatment Related Post-CAR Myeloid Neoplasms Save
- Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma. Save
- Chronic disseminated candidiasis in a patient with acute leukemia - an illustrative case and brief review for clinicians. Save
- Cardiovascular collapse and McConnell's sign as early manifestations of leucostasis. Save
- Lisocabtagene maraleucel for treatment of relapsed and refractory primary mediastinal large B-cell lymphoma in an adolescent patient. Save
- Analysis of PET-CT Derived Radiomic Biomarkers with Efficacy, Safety, and Expansion of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL) Save
- Impact of Obesity on Efficacy, Safety, and Expansion Kinetics of Chimeric Antigen Receptor-T (CAR T) Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma (LBCL) Save
- Second-Line Chimeric Antigen Receptor T Cell Therapy (CAR-T) As Standard of Care for Relapsed-Refractory Large B-Cell Lymphoma (LBCL) Save
- Leukostasis-induced digital ischemia. Save
- Interim Results of a Prospective Trial Testing Vaccination Against Pneumococcus before and after CD19 CAR T Cell Therapy to Optimize Humoral Immunity Save
- A Tale of Two Rashes in a Bone Marrow Transplant Patient. Save
- Pneumococcal Conjugate Vaccine Does Not Induce Humoral Response When Administrated Within the Six Months After CD19 CAR T-Cell Therapy. Save
- Bacillus Cereus bacteremia complicated by brain abscess in a severely immunocompromised patient: Addressing importance of early recognition and challenges in diagnosis. Save
- CPX-351 Yields Similar Response and Survival Outcome in Younger and Older Patients With Secondary Acute Myeloid Leukemia. Save
- Antibodies Against Vaccine-preventable Infections After CD19 or BCMA CAR T-cell Therapy Save
- Aggressive natural killer cell leukemia: diagnosis, treatment recommendations, and emerging therapies. Save